Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Growth in Short Interest

Eterna Therapeutics Inc. (NASDAQ:ERNA) saw a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 36,600 shares, a growth of 10.2% from the August 31st total of 33,200 shares. Based on an average daily trading volume, of 8,900 shares, the short-interest ratio is presently 4.1 days. Currently, 1.3% of the company’s shares are short sold.

Eterna Therapeutics Trading Down 7.0 %

ERNA stock traded down $0.07 during trading on Tuesday, reaching $0.98. 17,647 shares of the stock were exchanged, compared to its average volume of 13,617. The firm has a market capitalization of $5.28 million, a price-to-earnings ratio of -0.25 and a beta of 4.43. The company has a current ratio of 0.37, a quick ratio of 0.37 and a debt-to-equity ratio of 3.03. The business has a 50 day moving average price of $1.64 and a 200-day moving average price of $1.89. Eterna Therapeutics has a 1 year low of $0.84 and a 1 year high of $2.63.

Eterna Therapeutics (NASDAQ:ERNA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($1.02) earnings per share (EPS) for the quarter. The company had revenue of $0.05 million during the quarter. Eterna Therapeutics had a negative net margin of 14,765.43% and a negative return on equity of 1,466.71%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Lake Street Advisors Group LLC acquired a new position in shares of Eterna Therapeutics during the fourth quarter worth $933,000. Sippican Capital Advisors boosted its stake in shares of Eterna Therapeutics by 34.7% during the first quarter. Sippican Capital Advisors now owns 72,800 shares of the company’s stock worth $175,000 after buying an additional 18,750 shares during the period. Finally, Avidian Wealth Solutions LLC purchased a new position in Eterna Therapeutics in the 1st quarter valued at $36,000. 70.55% of the stock is owned by institutional investors and hedge funds.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.